Non-invasive system and method for monitoring lusitropic myocardial function in relation to inotropic myocardial function

ABSTRACT

A system and method for non-invasively monitoring the hemodynamic state of a patient by determining on a beat-by-beat basis the ratio of lusitropic function to inotropic function as an index of myocardial well-being or pathology for use by clinicians in the hospital or by the patient at home. In one embodiment of the system a smartphone running an application program that is connected through the internet to the cloud processes electronic signals, first, from an electrocardiogram device monitoring electrical cardiac activity, and second, from a seismocardiogram device monitoring mechanical cardiac activity in order to determine such ratio as an instantaneous measurement of the hemodynamic state of the patient, including such states as sepsis, myocardial ischemia, and heart failure.

CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of U.S. Provisional Application No. 62/238,330 filed Oct. 7, 2015.

FIELD OF THE INVENTION

The instant invention relates to a non-invasive system and method to monitor cardiac parameters, specifically lusitropic myocardial function in relation to inotropic myocardial function on a beat by beat basis in order to assess myocardial well-being or pathology on a real time basis.

BACKGROUND OF THE INVENTION 1. The Problem to be Solved

Lusitropic function is the ability of the left ventricle to relax during diastolic filling, following maximal left ventricular tension, and ejection of the stroke volume with each heartbeat during systole. Inotropic function is the ability of the myocardium to develop tension and pressure in the left ventricle during systole. Quantifying lusitropic function, and lusitropic function in relation to inotropic function, is the key to quantifying acute conditions, such as myocardial ischemia, myocardial infarction, and sepsis. At present, there is no non-invasive way to quantify lusitropic function during the relaxation and filling phase of the cardiac cycle. Nor is there such a way to quantify lusitropic function in relation to inotropic function on a beat-by-beat basis.

At present, the state-of-the-art in the measurement of myocardial ischemia consists in the measurement of ST segment elevations or depressions on an EKG. Modern technology has permitted the use of computer learning devices that can measure the baseline ST segment position, and report to the operator any upward or downward deviation in the ST segment (in mm) that may evolve during surgery, or during an ICU stay. This technology misses a large fraction of the episodes of ischemia that may occur in parts of the heart whose electrical vectors are not well aligned with the electrical axes represented by the EKG leads that are being monitored, typically Lead II and Lead V.

Also, modern trials of new medications for the treatment of sepsis have suffered from the lack of a clear clinical decision point early in the natural history of sepsis that defines precisely when to use a drug, and on precisely whom to use it.

Inotropic function can be measured invasively as the maximal value of the first derivative of left ventricle (“LV”) pressure during systolic contraction. Conversely, lusitropic function can be quantified as the absolute value of the most negative dip in the first derivative of LV pressure during diastolic relaxation. In the ASA Abstract published by the inventor, Torjman, and Goldfarb, in 2011 (the “Abstract”), a pig model of sepsis showed a clear and sudden reversal in the ratio of lusitropy to inotropy on a beat-to-beat basis, from greater than 1 to less than 1 exactly 14 minutes after the experimental placement of a clot of specially chosen E. Coli bacteria in the peritoneum of the pig. This is likely due to the signal effects of the interleukin storm that precedes frank sepsis, upon the contractile nano-machinery of the myocardium. The brevity of that 14-minute interval is constitutes an important step forward in monitoring heart problems. By contrast, conventional metrics of cardiodynamic function such as blood pressure, stroke volume, or cardiac output take hours before they show signs of deterioration during experimental sepsis. So, the data shows that this ratio of lusitropic to inotropic function can serve as an early warning sign of cardiac decompensation in sepsis. But in the experiment, this required the invasive placement of a solid-state pressure transducer at the end of a catheter directly into the left ventricle. If it were possible to detect this inversion of the ratio of lusitropy to inotropy cheaply, routinely, and non-invasively, then clinicians would be empowered to treat each patient with sepsis with appropriate medication, however expensive it may be, with high reliability, sensitivity, and with few false positives and false negatives. In other words, the “number needed to treat” (“NNT”), would be low. This new capability would remove a great deal of the “noise” in clinical trials of new medications for the treatment or palliation of sepsis. That, in turn, would allow any clinical trials of new medications to be conducted conclusively, on small numbers of patients, in significantly less time, and at much lower cost than is possible at present. This should be of great interest to the pharmaceutical industry.

Moreover, at the present time, there is no inexpensive, convenient, continuous way to monitor, or precisely quantify the natural history of congestive heart failure, understood as inotropic failure, or heart failure without preservation of ejection fraction. Similarly, there is no such way to monitor or quantify the natural history of diastolic heart failure, understood as lusitropic heart failure, or heart failure with preservation of ejection fraction (“HFpEF”). The latter category accounts for about 50% of all cases of heart failure. Such a capability would be useful as new and better drugs and treatments emerge over time. This advancement would also be useful for hospice and palliative care, as a way of sharpening prognosis in these usually fatal conditions and would be of interest to the life insurance industry as a low cost method of risk assessment.

2. A Description of the Prior Art

In addition to the Abstract, the inventions relating to non-invasive methods of monitoring cardiac parameters that are disclosed in the following patents to Hirsh, the inventor of the instant invention, relate to the field of the instant invention: U.S. Pat. No. 7,054,679, U.S. Pat. No. 7,657,306, and U.S. Pat. No. 8,843,194 (the “'194 patent”). Certain hardware technology relevant to the system of the present invention is described in the New York Times Article of Oct. 9, 2014 by Nick Bilton titled “Wearable Technology, Warts and All,” as well as in the Anh Dinh article from the 2011 Conference on Biomedical Engineering and Technology titled “Heart Activity Monitoring on Smartphone.”

SUMMARY OF THE INVENTION

Researchers have worked to develop non-invasive methods to measure cardiac output and indices of preload and afterload; however, to date there is no solution that allows for non-invasive measurement of lusitropy, except as it relates to acute myocardial ischemia, where lusitropy rapidly and dramatically decreases, and only then, as shown by the depression or elevation of the ST segment of an EKG with ischemia. Nor has anyone solved the problem of determining in a non-invasive way the beat-by-beat relationship between inotropy and lusitropy as an index of myocardial well-being or pathology.

The overriding issue is that by the time these other metrics, such as blood pressure, cardiac output, or stroke volume, start to diminish acutely, the patient is already well along his way down the slippery slope of decompensation and death.

The instant invention based on non-invasive monitoring provides for real time diagnosis and treatment of the following cardiac problems:

-   -   A. The sepsis studies show that in sepsis, lusitropy, in         relation to inotropy, declines in a sentinel fashion, well         before these other metrics. This new invention gives clinicians         more time to intervene.     -   B. Similarly, in the context of myocardial ischemia, an         ST-segment depression is a late sign of an imbalance between         oxygen supply and demand, in favor of demand. It is well known         that regional wall motion abnormalities (“RWMAs”) on a two         dimensional echocardiographic image of the left ventricle in         cross section precede ST-segment depression by several minutes.         It is likely that a decline in lusitropic function precedes         RWMAs in the context of myocardial ischemia. That would give         clinicians a longer window of opportunity in which to restore         oxygen supply and demand balance, and allow them to prevent         myocardial ischemia and infarction in the first place.     -   C. Noninvasive measurement of the relation between lusitropy and         inotropy can serve to diagnose and monitor heart failure and         HFpEF, also known as diastolic heart failure. At present,         diastolic heart failure is diagnosed when a patient has signs         and symptoms of heart failure, but has a normal ejection         fraction on two dimensional echocardiogram. Alternatively, an         elevated BNP level in the presence of a normal ejection fraction         or stress echocardiogram is necessary to make the diagnosis. The         present invention represents a cheaper, more reliable way to         make the diagnosis and quantify the natural history and         treatment of HFpEF. It uses real time physiologic metrics rather         than imaging or laboratory values of blood biomarker         concentrations.         -   In the prior art there are no teachings on how to make             myocardial lusitropy the subject of routine noninvasive             clinical assessment, particularly in a way that is             dynamical, and not anatomical or volumetric. The present             invention is founded upon a novel and recently predicted and             demonstrated principle of physiology. Up until now, the LV             was a clinical ‘black box’ with respect to actual pressure             measurements, and time derivatives of pressure measurements,             except for short periods of time in the cardiac             catheterization laboratory. The procedure done there is             hazardous, with risk for fatal arrhythmias, infection, and             hemorrhage. It uses expensive disposables, and generates a             great deal of infectious waste, whose disposal is expensive.             Cardiac catheterization is only undertaken by highly             trained—and highly compensated—interventional cardiologists.             It is certainly not at all well suited to clinical             monitoring, let alone telemedicine. The present technology,             by contrast, is very well suited to the enterprise of             telemedicine.

In the '194 patent, the inventor of the present invention taught that, based on the experimentation results set forth therein, there exists an electromechanical interval (E−M) where the E-event is defined by the time of the second derivative maximum represented near the Q-wave in the QRS complex of the EKG. The M-event is defined as the time of the second derivative maximum of the peripheral pulse pressure wave, as detected by a radial or other peripheral arterial catheter pressure transducer. The patent teaches, among other things, that 1/(E−M) is linearly proportional to the natural logarithm of the maximum value of the first derivative of systolic pressure in the left ventricle. That is, ln(LVP′max)=A+B/(E−M),

where A, B are personal constants.

While this methodology works well in patients who are having surgery under anesthesia, or patients in ICU beds, it is not well suited to measurements on ambulatory patients because the wrist can be arrayed with many degrees of freedom at many levels with respect to the heart. The resulting changes in DC hydrostatic pressure in the column of vertical fluid between the heart and the transducer has a huge effect on the speed of the pulse wave, and hence on the time differential, (E−M). The torsional, flexional, and extensional motions of the wrist play havoc with acoustic or mechanical coupling between the skin-mounted transducer and the pressure wave in the underlying artery.

Moreover, it is extremely difficult to transduce the radial arterial pulse wave through skin over the radial artery using existing transducer technology. The signal to noise ratio of extant accelerometers or strain gauges is too low to make a clinically reliable measurement. Finger cuffs (Edwards' ‘Nexfin’) and electro-mechanically applanated piezoelectric transducers (Tensys Medical's ‘T-Line’) have been used, with some end-user and reliability obstacles, to measure blood pressure and other hemodynamic parameters. So in order to measure the inotropic function of the heart on an ambulatory basis, it is necessary to find another, non-invasive, way to determine the M-event, which is described herein.

By allowing lusitropic function to be quantified non-invasively, the present invention can serve to inexpensively, safely, and reliably diagnose and monitor HFpEF, as well as the efficacy, or inefficacy of therapeutic medications and procedural interventions for cardiac problems across the spectrum. It is also key to quantifying chronic conditions characterized by poor lusitropic function, such as diastolic heart failure, or HFpEF, and its several causes, such as hypertension, diabetes, aortic stenosis, constrictive pericarditis, and restrictive cardiomyopathy, including amyloidosis, sarcoidosis and fibrosis. By allowing lusitropic function to be quantified non-invasively, the present invention can serve to inexpensively, safely, and reliably diagnose and monitor HFpEF, as well as the efficacy, or inefficacy of therapeutic medications and procedural interventions. The technology can serve in one embodiment as a bedside monitor in hospital, or, combined with smartphone and Internet connectivity, the invention can also serve in another embodiment as a new window into myocardial function in the emerging world of telemedicine, helping to deliver better, faster, cheaper, safer care, in a way that radically increases access to care for large communities of people who are not now being well served by the existing health care system. This telemedical measurement, characterization, and cloud storage of the patient's ‘Physiome’ data, owned by the patient, is well described in Dr. Eric Topol's recent book, ‘The Patient Will See You Now’ (Basic Books, 2015).

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a block diagram of one embodiment of the non-invasive system of the present invention.

FIG. 2 is a flow chart for non-invasive monitoring of a patient using the algorithm and teachings of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

One object of this invention is to provide an inexpensive, safe, continuous, non-invasive, metric based on lusitropic function, and lusitropic function relative to inotropic function on a beat-to-beat basis, that is determined in a non-invasive manner, that allows for continuous monitoring in the emerging smartphone-connected telemedicine space. Another objective is to improve access to care by removing traditional obstacles to clinical assessment and diagnosis by measuring a physiologic cardiodynamic quantity that is not now being measured on a non-invasive basis, whose decompensation results in at least three categories of disease: myocardial ischemia, sepsis, and heart failure, whose costs are huge and whose consequences are devastating. The system of the present invention is comprised of at least one electrocardiographic lead containing an electrode, preferably lead II, but it should be noted that the preferred embodiment employs greater accuracy by using three leads having electrodes 21, 22, and 23 as shown in FIG. 1, those being lead V, and lead I in addition to lead II, by which electronic signals measuring electrical activity of the heart are obtained and digitized; a phonocardiogramic signal, obtained from a microphone 24 placed directly over the heart on the chest, and/or a seismocardiogramic signal, obtained from an accelerometer 25 placed directly over the heart, each of which having therein a converter as identified in boxes 24 and 25 in FIG. 1 to convert the mechanical data from the microphone or accelerometer into electronic data which is digitized; and a computer platform 20 in FIG. 1, including a display 12, to run the software needed to process the (i) the digitized electronic data stream that is input from connections to the processor 11 of the computer platform 20 from the electrocardiogram at the same time as (ii) the digitized electronic data stream that has been converted from the mechanical data from the microphone or accelerometer, each of which being input by connections to the processor of the computer platform from the electrical and mechanical systems described above in accordance with the algorithm described in this specification. The computer platform in one embodiment is comprised of a smartphone with internet and cloud connectivity on which the algorithm described herein runs as an application program. The phonocardiogramic devices or seismogramic devices can be used interchangeably, or to complement one another so as to make the measurement more robust. Optionally, this can be in the form of wearable ‘skin tattoo’ circuitry such as the devices made by MC10, which contain Blue-Tooth connectivity for a microelectromechanical system (“MEMS”) microphone as well as MEMS accelerometer transducers as described in the article referenced above. Seismocardiogram technology as described by Anh Dinh, supra, can be conveniently placed on the chest, over the heart, near the point of maximal impact, typically in the 5^(th) intercostal space in the mid-clavicular line. FIG. 1 shows the system 10 comprised of three EKG leads 21, 22, and 23 (respectively, lead II, lead V, and lead I) connected to a processing unit 20 through connectors 31, 32, and 33, respectively, to which are also connected a microphone with built in converter 24 through connector 34 and an accelerometer with built in converter 25 through connector 35. In another embodiment, the physical connectors 34 and 35 are replaced by the use of wireless technology, such as Blue Tooth technology, linking the microphone 24 electronic output and/or accelerometer 25 electronic output through directly to the processor 11 in the computer platform 20 of FIG. 1.

The system described above provides non-invasive metrics of inotropic and lusitropic function. Optionally, this system can provide stroke volume and cardiac output information, non-invasively on patients who are bedbound, or ambulatory, via their smartphone connectivity, which information can then be uploaded the to the cloud for processing.

This system can algorithmically extract useful, actionable clinical knowledge about the patient's condition and response to treatment, from a massive amount of data obtained from transducer streams as described and can be used for diagnosis as well as management, that is, to reliably detect useful signal and separate that from noise as described herein.

The goal is to algorithmically detect significant changes in the patient's cardiac status earlier in the natural history of decompensation than is achievable in the prior art, especially in patients known from their prior co-morbidities to be at risk, and to create longer windows of opportunity to intervene, as well as to prevent unnecessary hospitalization with its attendant inconvenience and expense.

The use of the system in the method of the present invention is founded upon a novel and recently predicted and demonstrated principle of physiology as described in the Abstract. The principle will be readily apprehended by review of the Wiggers Diagram, well known to those practiced in the art, which shows the simultaneous traces of EKG, left ventricular pressure (“LVP”), arterial blood pressure (“ABP”), with a phonocardiogram, throughout the cardiac cycle. The lusitropic event, where the myocardium maximally relaxes after systole, is always heralded electrically on the EKG by the T-wave, referred to as the “Lightning.” The closure of the aortic valve is audible as S2 in the phonocardiogram which announces to the informed listener that the moment of most rapid loosening of the myocardium in diastole has just occurred, which is referred to as the “Thunder.” By measuring the interval, in milliseconds, between the Lightning and the Thunder, it is possible to accurately quantify the lusitropic state of the myocardium because the Lightning-‘Thunder, or (E−M) lusi, interval, other things being equal, becomes longer when the heart loses its lusitropic function, providing an accurate metric of the stiffness of the heart muscle in diastole, as the heart relaxes from its full-on contraction state and the LV begins to fill. This ability of the myocardium to relax is lost for instance, during ischemia, simply because relaxation of myocardium after systolic contraction is an oxygen-requiring process, where cross-links between actin and myosin fibrils are broken in an ATP-requiring, energy-requiring process. An ischemic, oxygen-starved heart is a stiff, inelastic heart. Having lost its systolic tension, the ischemic myocardium is unable to spring back to an unfilled state of low wall tension with its usual speed. This change can be accurately measured. Conversely, other things being equal, a heart that is well perfused with high oxygen-content arterial blood, will relax very quickly, and the Lightning-Thunder interval will be measurably shorter.

Similarly, during sepsis, a myocardium that is at the center of an interleukin and acute phase reactant storm, may have one or more of the complex molecular contractile nanomachines that make up the myocardium acutely inhibited in a way that is now measurable, cheap, and harmlessly non-invasive.

And lastly, this present invention brings more precision to the diagnosis of diastolic heart failure, or heart failure with preserved ejection fraction. The value of (E−M) lusi at rest, and with moderate exercise, above a population normalized threshold value, may of itself be diagnostic of HFpEF.

FIG. 2 is a flow chart that presents the steps under the control of the algorithm of the present invention used by the presently invented, non-invasive system. A patient with signs of one of a number of possible heart problems or trauma as described therein (such as, without limitation, ischemia, heart failure, sepsis, and myocardis) is non-invasively monitored by the system described above. The left side of the block diagram describes the steps used in the non-invasive collection of electrocardiogram data and generating a number which is related to lusitropic function which are: obtaining voltage measurements as a function of time; digitizing such data; using the algorithm described herein on such data to smooth and provide time derivatives thereof, including the second derivative thereof; extracting the first peak of the Q wave and first peak of the T wave; and calibrating by mapping 1/(T″−Q″) to ln(LVP′) and/or mapping 1/(S1″−Q″) to ln (LVP) which gives the number related to lusitropic function. The right side of the block diagram describes the steps used in the non-invasive collection of mechanical input data and generating a value that is related to inotropic function which are: obtaining a voltage measurements as a function of time corresponding to sound amplitude from the mechanical input device; digitizing such data; using the algorithm described on such data to smooth and provided time derivatives thereof, including, the second derivative thereof; applying the well known methods of Fourier transformation to such function and applying a low pass filter to limit the result to frequencies below 50 hertz; extracting the peak of that function to derive S1 and S2; obtaining the timing and magnitude of S1 and S2; and calibrating by mapping 1/(S2″−T″) to ln abs LVPmin and mapping 1/(S1″−Q″) to 1/(T″−Q″) which gives the value related to inotropic function. The ratio of the first such value to the second such value provides a measurement of lusitropic myocardial function to inotropic myrocardial function which can then be used by the end user who is either a clinician in a hospital setting, or the patient by himself or herself, while at home.

It should be noted that with respect to the steps of the collection of mechanical input data that the application of the Fourier transform to the voltage as a function of time representing sound can also be effective when such application precedes the smoothing and time derivative operations.

The algorithm referenced above as used by the present system and method can be further explained as follows:

-   -   1) In the (E−M)lusi interval, a metric of diastolic function,         the E-event is the time of the maximum value of the second         derivative of the EKG at first peak of the T-wave.     -   2) In the (E−M)lusi interval, the lusitropic M-event is the time         of the maximum value of the second derivative of the amplitude         signal of the phonocardiogram, either pre-cordial, for         ambulatory patients, or esophageal in anesthetized or intubated         critical care patients. In (E−M)lusi, the Lusitropic M-event         corresponds to the S2 heart sound on the phonocardiogram. This         can be seen in the well known Wiggers Diagram.     -   3) In the (E−M) lusi interval, the lusitropic M-event can also         be the maximum value of the first peak in the cardiac seismogram         following the second peak in the second derivative of the T-wave         on EKG, such as that which is labeled “AC” (“aortic valve         closing”).     -   4) Alternatively, the M-event can be the peak in the first or         second derivative of the cardiac seismogram following the first         peak in the second derivative of the T-wave on EKG.     -   5) The two embodiments of (E−M) lusi can be measured         simultaneously and mapped one against the other, cumulatively in         real time. The slope and intercept of this linear relation can         be characterized in an epochal or running fashion. This serves         to increase the robustness of the system, should there be an         interruption in either the phonocardiogram or the cardiac         seismogram. The missing data can be interpolated from the         ongoing ‘calibration’ relation between the two species of (E−M)         lusi. Each measurement serves as a reality check on the other in         a way that is opaque to the end user.     -   6) To a useful approximation,         ln(abs(LVP′min))=A1+B1/(E−M)lusi  Equation 1

In other words, this absolute value of the most negative value of the first derivative of pressure in the left ventricle during diastolic relaxation, is linearly proportional to 1/(E−M)lusi. This will work whether the M-event is derived from phonocardiographic or cardiac seismographic data. Optionally, A1 and B1 can be shown, to a useful approximation, to be empirical functions of height, weight, age, and gender. It may be noted that this is possible, but not necessary, inasmuch as clincians do not ordinarily trouble themselves to know the values of the first derivative of LVP (LVP′max) in systole, and they will be well served by a numerical index that is monotonically or linearly increasing with respect to LVP′min during diastolic relaxation of the myocardium.

-   -   7) The power law that relates the maximum value of the first         peak in the second derivative of the T-wave voltage to the         absolute value of the maximally negative value of the first         derivative of LV pressure in diastole, LVP′min, gives a useful         approximation, so that         ln(EKG″max)_(T-wave) =A2+B2(ln(ABS(LVP′min))  Equation 2     -   Since two quantities that are proportional to the same quantity         are proportional to each other, it follows that ln(EKG″max)         T-wave is proportional to 1/(E−M)lusi. Hence, the quantity ln         (EKG″max) T-wave for the ith consecutive heartbeat can serve as         an alternative or simultaneous index of lusitropic function.         Since it is easily calculated from the existing data stream, the         algorithm can plot ln(EKG″max)_(T-wave) as a function of         1/(E−M)lusi, and calculate the slope and intercept of the         resulting function in a cumulative, epochal, or running fashion.         This will increase the robustness of the system, since if one         data stream drops out, its quantity can then be easily         interpolated from the other and serves as a reality check on the         other measurements. The changes in slope of the function that         relates these two noninvasive indices may indicate subtle         changes in inotropic function.     -   8) Simultaneously, the algorithm calculates (E−M)ino. This         metric of the contractile, inotropic function of the myocardium         shortens with increasing inotropy, as measured by the natural         log of the first derivative of the left ventricular pressure in         systolic contraction, that is, ln(LVP′max).     -   9) The E-event in (E−M)ino is the time of the second derivative         maximum in the EKG voltage(t) function that corresponds nearly         to the Q-wave in the QRS complex that heralds electrical systole         on the EKG.     -   10) The inotropic M-event is the time of the maximum value of         the second derivative of the phonocardiogram amplitude(t)         function that corresponds to the S1 heart sound can be seen on a         Wiggers Diagram, yielding:         ln(LVP′max)=A3+B3/(E−M)ino  Equation 3     -   11) An alternative inotropic M-event can be derived from the         cardiac seismogram. This can be the peak labeled “MC” denoting         mitral valve closure.     -   12) The M-event can optionally be the peak in the first or         second derivative of the cardiac seismogram that occurs just         prior to MC. The optimal embodiment still needs to be determined         empirically.     -   13) There exists an intropic interval (E−Et) that derives         entirely from the EKG voltage as a function of time data steam         having properties similar to (E−M)ino. Here, the E event is         still the time of the second derivative EKG voltage(t) maximum         that corresponds to the Q-wave of the QRS complex that heralds         electrical systole. The Et event is the time of the second         derivative EKG voltage(t) peak that corresponds to the beginning         of the T-wave. In the second derivative, the T-wave has 2 peaks,         separated by a time interval Delta t″_(T-wave). The Et event         corresponds to the first of these two peaks in the second         derivative of the T-wave. There is evidence to show that, in         cardiac systole,         ln(LVP′max)=A4+B4/(E−Et)  Equation 4     -   Again, since 1/(E−Et) and 1/(E−M)ino are both proportional to         ln(LVP′max), that they are proportional to each other. It         follows that (E−Et) and (E−M)lusi are also linearly         proportional. The algorithm can map (E−Et) to (E−M)lusi in a way         that increases the robustness of the system and allows missing         data points to be interpolated from the linear relation. The         fitting parameters of the linear relation can be calculated         cumulatively, by data epoch, or in running fashion. We         hypothesize that changes in the slope of this relation may         indicate subtle changes in inotropic function which can be         tested empirically. The time intervals (E−Et) and Delta         t″_(T-wave) may yield information about circulating cation         concentration in the blood. For instance, Delta t″_(T-wave) may         correlate usefully with K+ concentration. Alternatively, the         integral under the T-wave between the limits of the two         EKG″peaks in the T-wave that define Delta t″_(T-wave) may serve         the same purpose. 1/(E−Et) may predict circulating Ca++ in a way         that is actionable, once the functions are appropriately         calibrated with real Ca++ values.     -   14) Having the two metrics for both ln(LVP′max) and ln(LVP′min)         for the ith consecutive heartbeat, and following the example in         the Abstract, we want to create a metric of the ratio of         [LVP′min/LVP′max] knowing that the ratio is greater than 1 in         health, but that it decreases rapidly in septic shock, and         deteriorates further in the natural history of the condition.     -   15) But by the properties of logarithms,         ln(abs(LVP′min)/LVP′max)=ln(LVP′min)−ln(LVP′max)  Equation 5     -   We can substitute for the terms in the right hand side of eq. 5         such that         ln(abs(LVP′min)/LVP′max)=[A1+B1/(E−M)lusi]−[A3+B3/(E−M)ino]     -   Rearranging terms,         ln(abs(LVP′min)/LVP′max)=[A1−A3]+B1/(E−M)lusi−B3/(E−M)ino  Equation         6     -   Empirically, it is useful to create a large library of data         taken from hundreds or thousands of cardiac catheterizations of         the Left Ventricle with simultaneous values of (E−M)lusi,         (E−M)ino, LVP′max, and LVP′min. This can be combined with data         on height, weight, gender, age, rhythm, QRS width, Q-T interval,         ln(EKG″max)_(T-wave), and 1/(E−Et) for each heartbeat in the         data set. From this data, we create a look-up table for expected         values of A1, B1, A3, and B3, which is not necessary presently         for creating a non-invasive metric that tracks linearly with the         lusitropic/inotropic ratio as described in the Abstract. We know         empirically from the Abstract that for pigs in robust health the         ratio LVP′min/LVP′max has a value around 1.4. The natural log of         1.4 is about ⅓. Assume that A1 and A3 are about the same size.         So, they cancel out in Eq. 6. Then,         B1/(E−M)lusi−B3/(E−M)ino=⅓  From Equation 6     -   B1 and B2 are constants. Assuming a state of health, or         physiologic non-decompensation, for a particular patient, and         that the patient had been previously studied sufficiently in         that state so that we are given mode and mean values of         (E−M)lusi and (E−M)ino in that same state of health. Since         1−⅔=⅓, we arbitrarily adjust B1 and B2 so that         B1/(E−M)lusi=1, and         B2/(E−M)ino=⅔     -   and at least heuristically, B1 and B2 are determined.     -   For the purpose of monitoring, we create a function         Qi=exp(B1/(E−M)lusi−B3/(E−M)ino)  Equation 7     -   where i is the ith heartbeat.     -   This useful function serves as a noninvasive metric of the         lusitropic/inotropic ratio described in the Abstract. The         monitoring process described herein can be used over hours,         days, months, or years. Further, we can examine the function         Qbar=(1/i)Sigma(Qi) over a respiratory cycle, or an epoch of ‘n’         consecutive respiratory cycles, or in a running fashion. If the         function Qbar were to suddenly deteriorate, that might be an         early signal that the patient was struggling with septic shock.         If the patient's personal value of Qbar were well known from         long and prior measurement, or calculated on admission to an ICU         before the placement of a central line, and it were to suddenly         decrease relative to baseline, the clinician is given cause to         think that some septic process had been initiated, just like in         the pig experiment in the Abstract. In a patient with a long         history of ischemic cardiomyopathy, or HFpEF, then 1/(E−M)lusi         would be a smaller quantity than normal, and hence the quantity         1/(E−M)lusi−1/(E−M)ino would have a smaller baseline level.         Still, if that patient were to be admitted to the ICU where a         central line was started, and the quantity         1/(E−M)lusi−1/(E−M)ino were to suddenly deteriorate as shown in         the Abstract, a clinician could make the same inference about         sepsis as in the case of a healthy individual. If this co-morbid         patient were admitted to the OR for a hip fracture, it would be         possible to download his values of (E−M)lusi and (E−M)ino from         the cloud, and use them as the basis for monitoring for episodes         of increased myocardial ischemia, and intervene appropriately         with, for example, nitrates, oxygen, PEEP, or beta-blockers. For         a patient is admitted to a hospital with heart failure, either         with or without preserved ejection fraction, personal monitoring         under the present system could be done while ambulatory         constantly using smartphone connectivity. This capability would         provide early warning signs of decompensation, to physicians,         and to patients via text messages with appropriate instructions         for remediation, and opportunities for intervention, to keep         people with congestive heart failure out of the hospital, albeit         on constant non-invasive monitoring.     -   16) Teachings in the '194 patent are relevant with respect to         the current system in measuring stroke volume, with the result         that the product of stroke volume and heart rate measures         cardiac output, based on using an (E−M)ino value. The two         species of (E−M)ino values described here will serve, as will         (E−Et), the latter being derived exclusively from the EKG         signal. The '194 patent teaches that ln(SV/EI) is proportional         to ln(LVP′max). Here SV is stroke volume, and EI is the ejection         interval. This is essentially a statement of a power law         relating these two quantities. The quantity SV/EI is just the         average rate of blood outflow from the LV into the aorta during         systolic ejection. Knowing SV/EI from a non-invasive         measurement, and knowing EI, allows the calculation of their         product, stroke volume. A novel approach to measuring EI is to         use the cardiac seismogram obtained from a precordial         accelerometer that is part of, in one embodiment, a skin tattoo         circuit with blue tooth connectivity as referenced earlier. To         measure EI, one need only subtract the time of the peak         designated AO from the time of peak AC as trace of the cardiac         seismogram. An algorithm can be taught to look for these peaks         following the EKG R-wave and T-wave respectively. Optionally,         the seismogram can be used to identify the opening of the aortic         valve AO, and the phonocardiogram can be used to identify the         closing of the aortic valve as S2. In both these cases, the         signal to noise ratio is optimally high.     -   From the teachings of the '194 patent,         ln(SV/EI)=A4+B4/(E−M)ino  Equation 8     -   Solving for SV, we get         SV/EI=exp[A4+B4/(E−M)ino]=exp(A4)*exp(B4/(E−M)ino), and         SV=EI*{exp(A4)*exp(B4/(E−M)ino)}  Equation 9

Compared to the teachings of the '194 patent, this approach has the advantage of being independent of the length of the patient's arteries, or the path length from the aortic valve to the detector over the radial artery. Using large amounts of patient data obtained using a fiducial cardiac output or stroke volume measurement technology, and combining that with patient data such as height, weight, age, and gender, it is possible to create a look-up table for expected values of A4 and B4 that are well founded in clinical reality. The system of the present invention allows for lusitropic, inotropic and stroke volume and cardiac output to be cheaply and non-invasively monitored on recumbent as well as ambulatory people, using just a skin tattoo circuit with MEMS transducers and blue tooth connectivity, and a smartphone with an Ethernet connection or otherwise connected to the Internet by simply wearing a skin patch and carrying a smartphone, a truly disruptive breakthrough in terms of the detection and mitigation of devastating and costly illness early in its natural history.

While it is the intention of this application to describe preferred embodiments of the instant invention, the present application should not to be read so as to preclude its coverage of similar embodiments of the system of the present invention that can be used to achieve the desired results of monitoring and patient care using the methods and the algorithms described herein. 

What is claimed is:
 1. A system for non-invasive monitoring of cardiac activity of a patient comprising: a non-invasive electronic heart function measurement device providing electronic outputs related to lusitropic and inotropic electrical cardiac activity; a non-invasive mechanical heart function measurement device providing mechanical outputs related to lusitropic and inotropic mechanical cardiac activity; a converting unit connected to said mechanical heart function measurement device for converting said mechanical outputs of said device into electronic outputs related to said mechanical cardiac activity; a computer platform comprising a processing unit and a display; a connection from the output of said electronic heart function measurement device to the input of said processing unit; and a connection from the output of said converting unit to the input of said processing unit; whereby said processing unit processes said inputs relating to said electronic outputs related to said electrical cardiac activity and said electronic outputs related to said mechanical cardiac activity in order to determine intervals between such inputs relating to electrical cardiac activity and such inputs relating to mechanical cardiac activity and comparing such intervals with the results of such comparisons being output to said display providing for real time monitoring of lusitropic myocardial function, inotropic myocardial function, and the ratio of lusitropic myocardial function to inotropic myocardial function on a beat by beat basis in order to assess myocardial well-being or myocardial pathology of a patient.
 2. The system of claim 1 in which the non-invasive electronic heart function measurement device is at least one electrode that is mounted in an electrocardiogramic lead.
 3. The system of claim 2 in which the electrocardiogramic lead is lead II.
 4. The system of claim 1 in which the non-invasive mechanical heart function measurement device is a microphone.
 5. The system of claim 1 in which the non-invasive mechanical heart function measurement device is an accelerometer.
 6. The system of claim 1 in which the computer platform is a smartphone connected to the internet.
 7. The system of claim 1 in which said connections are wireless.
 8. The system of claim 6 in which said smartphone is blue tooth capable.
 9. The system of claim 8 in which said connections are blue tooth connections.
 10. The system of claim 1 in which said non-invasive electronic heart function measurement device, said non-invasive mechanical heart function measurement device, and said converting unit are resident on an electronic skin tattoo circuit.
 11. The system of claim 10 in which said connections are wireless.
 12. The system of claim 10 in which said electronic skin tattoo circuit is blue tooth capable.
 13. The system of claim 12 in which said connections are blue tooth connections.
 14. The system of claim 13 in which said computer platform is a smartphone connected to the internet.
 15. The system of claim 14 in which said smartphone is blue tooth capable. 